Donepezil Hydrochloride Tablet
Product Images NDC 68180-527

17 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68180-527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezil Hydrochloride (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 01)

Donepezil Hydrochloride (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 01)
Chemical structure diagram of Donepezil Hydrochloride, illustrating the molecular arrangement including aromatic rings, ether groups, and the hydrochloride component.*
FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 02)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 02)
A line graph depicting ADAS-cog mean change from baseline over weeks of drug treatment up to 30 weeks. The chart compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, showing clinical improvement or decline on the vertical axis with error bars for standard error. The placebo phase is indicated after 24 weeks of treatment.*
FDA Label Image

Figure 2 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 03)

Figure 2 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 03)
This chart presents a cumulative percentage plot of patients showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride at 5 mg/day and 10 mg/day doses compared to placebo. The x-axis shows change from baseline, and the y-axis shows the cumulative percentage of patients. The graph indicates cognitive changes with corresponding treatment groups.*
FDA Label Image

Figure 3 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 04)

Figure 3 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 04)
A bar chart comparing the percentage of patients rated on the CIBIC-plus scale across three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo. The chart shows categories from Markedly Improved to Markedly Worse, depicting response distribution among these treatment groups.*
FDA Label Image

Figure 4 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 05)

Figure 4 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 05)
A line graph depicting ADAS-cog change from baseline over 15 weeks of drug treatment, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The Y-axis measures mean change with error bars, showing clinical improvement above baseline and clinical decline below. The X-axis shows weeks of treatment and a placebo phase, illustrating cognitive performance trends in each group.*
FDA Label Image

Figure 5 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 06)

Figure 5 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 06)
A line graph comparing the cumulative percentage of patients versus change from baseline on the x-axis, for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The graph shows different treatment effects over time with marked points at -7, -4, and 0 on the x-axis, and a legend indicating treatment groups and their respective percentages of change in ADAS-cog scores.*
FDA Label Image

Figure 6 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 07)

Figure 6 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 07)
A bar chart depicting the percentage of patients with different CIBIC-plus ratings after receiving Donepezil Hydrochloride 5 mg/day, 10 mg/day, or placebo. Ratings range from Markedly Improved to Markedly Worse, showing comparative patient outcomes across these three groups.*
FDA Label Image

Figure 7 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 08)

Figure 7 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 08)
A line graph comparing SIB (Severe Impairment Battery) change from baseline mean scores over 6 months of drug treatment between Donepezil Hydrochloride 10 mg/day and placebo groups. The y-axis shows SIB change from baseline (mean ± SE) with clinical improvement and decline indicated, and the x-axis shows months of treatment at 0, 3, and 6 months. Donepezil shows clinical improvement while placebo trends toward clinical decline.*
FDA Label Image

Figure 8 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 09)

Figure 8 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 09)
A cumulative percentage curve graph comparing the effects of Donepezil Hydrochloride 10 mg/day versus placebo on SIB (Severe Impairment Battery) score change from baseline in patients. The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentage of patients.*
FDA Label Image

Figure 9 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 10)

Figure 9 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 10)
A line graph comparing the mean change from baseline in ADCS-ADL scores over 6 months between Donepezil Hydrochloride 10 mg/day and placebo groups. The y-axis represents clinical improvement and decline, while the x-axis shows months of drug treatment. Donepezil shows less decline compared to placebo over time.*
FDA Label Image

Figure 10 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 11)

Figure 10 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 11)
This is a cumulative percentage line graph comparing patients treated with Donepezil Hydrochloride 10 mg/day versus placebo. The X-axis shows ADCS-ADL change from baseline, ranging from -20 to 15, while the Y-axis shows cumulative percentage of patients from 0 to 100. Two curves illustrate patient response distributions for each group.*
FDA Label Image

Figure 11 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 12)

Figure 11 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 12)
A line graph depicting SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment. It compares Donepezil Hydrochloride at dosages of 23 mg/day and 10 mg/day, with SIB change on the y-axis and weeks of treatment on the x-axis. The graph shows clinical improvement and decline relative to baseline.*
FDA Label Image

Figure 12 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 13)

Figure 12 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 13)
A cumulative percentage curve graph comparing SIB change from baseline between Donepezil Hydrochloride 23 mg/day and 10 mg/day groups. The x-axis displays SIB change values ranging from 50 to -60, while the y-axis shows cumulative percentage of patients from 0 to 100%. Two lines represent the different dosage groups, illustrating patient response distribution.*
FDA Label Image

Figure 13 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 14)

Figure 13 (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 14)
A bar chart presenting the percentage of patients by CIBIC-plus Rating for Donepezil Hydrochloride 23 mg/day and 10 mg/day. The x-axis shows patient improvement categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients within each category comparing the two dosages.*
FDA Label Image

Image (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 142 1)

Image (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 142 1)
The image shows a white and black blister card containing 10 round, white tablets of Donepezil Hydrochloride 23 mg. The packaging features the brand name DONEPEZIL HYDROCHLORIDE, with the strength 23 mg clearly indicated. The labeler, Lupin Pharmaceuticals, Inc., is mentioned. The tablets are arranged in two rows and sealed individually in the blister pack.*
FDA Label Image

Image (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 214 1)

Image (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 214 1)
DONEPEZIL HYDROCHLORIDE 23 mg oral tablets in a blister card packaging. The card contains 7 round tablets arranged in two rows. The labeler is Lupin Pharmaceuticals, Inc. The blister card has a clear plastic covering over each tablet and a gray backing with black text.*
FDA Label Image

Donepezil Hydrochloride Tabletsrx Only23 mgndc 68180-527-0630 Tablets (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 15)

Donepezil Hydrochloride Tabletsrx Only23 mgndc 68180-527-0630 Tablets (F8867ea9 A608 4b0f 9052 Fa5c44d7e7c2 15)
Label for Donepezil Hydrochloride Tablets USP 23 mg, oral tablets packaged in a 30-count bottle. The label includes storage instructions, manufacturer details (Lupin Pharmaceuticals, Inc. and Lupin Limited, India), and directs pharmacists to dispense the accompanying patient information leaflet. The NDC is 68180-527-06.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.